You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. GALMED PHARMACEUTICALS LTD

Galmed Pharmaceuticals Ltd XNAS: GLMD

Galmed Pharmaceuticals Ltd Live Share Price Today, Share Analysis and Chart

Download real time

1.74 -0.02 (-1.14%)

87.19% Fall from 52W High

33,880 XNAS Volume

XNAS 26 Mar, 2025 12:06 PM (EDT)

Watchlist

Portfolio

Share
Board Meeting
The next board meeting for Galmed Pharmaceuticals Ltd is on 04 Apr 2025 for the purpose of Galmed Pharmaceuticals Ltd Annual Report for 2024 See details

Galmed Pharmaceuticals Ltd Key Metrics

Default

Market Capitalization

Low in industry
2.9

PE TTM

Negative PE TTM
-0.5

Price to Book

Low in industry
0.2

Institutional holding current Qtr %

Low in industry
2.9

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-29.9

Net Profit TTM Growth %

Below industry Median
16.1

Piotroski Score

Below industry Median
1

Rel Perf vs Sector quarter%

-47

ROE Annual %

Negative ROE Annual %
-50.6

RoA Annual %

Negative RoA Annual %
-41.7
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
16.2 / 100
Momentum Score
Technically Bearish
18.6 / 100
Analyst Price Target
No estimates available

11

S

12

W

1

O

0

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Galmed Pharmaceuticals Ltd Live Price Chart

Switch to TradingView
Fetching data ...

Galmed Pharmaceuticals Ltd Stock Analysis

Galmed Pharmaceuticals Ltd stock analysis with key metrics, changes, and trends.

Galmed Pharmaceuticals Ltd MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$6.91 M8.27%positive

Annual Net Profit rose 8.27% in the last year to $6.91 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio-0.46-negative

Price to Earning Ratio is -0.46, which is negative.

Stock Price$1.74-54.69%negative

Stock Price fell 54.69% and underperformed its sector by 61.68% in the past year.

Quarterly Net profit$1.91 M29.94%negative

Quarterly Net profit fell 29.94% YoY to $1.91 M. Its sector's average net profit growth YoY for the quarter was -47.31%.

Debt to Equity Ratio--positive

Debt to Equity Ratio is zero as the company is debt-free.

Return on Equity(ROE)-50.63 %-50.63%negative

Return on Equity(ROE) for the last financial year was -50.63%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding0.10 %0%neutral

Mutual Fund Holding remained the same in the last quarter at 0.1%.

Institutional Holding2.94 %2.36%positive

Institutional Holding increased by 2.36% in the last quarter to 2.94.

VIEW LESS


Loading data..

Galmed Pharmaceuticals Ltd - Company Profile

What does Galmed Pharmaceuticals Ltd do?

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Galmed Pharmaceuticals Ltd Management structure

All Gross Remunerations are in USD
Mr. Allen Baharaff
Director, President and Chief Executive Officer
1.36 M
2022
Gross Remuneration
Year
Mr. Yohai Stenzler
Chief Accounting Officer
354.14 K
2022
Gross Remuneration
Year
Mr. Guy Nehemya
Chief Operating Officer and Data Protection Officer
350.21 K
2022
Gross Remuneration
Year
Dr. Liat Hayardeny
Chief Scientist Officer
239.89 K
2022
Gross Remuneration
Year
Mr. Doron Cohen
Chief Financial Officer
159.66 K
2022
Gross Remuneration
Year

Galmed Pharmaceuticals Ltd Board of directors

All Gross Remunerations are in USD
Dr. David Sidransky, M.D.
Lead Independent Director
-
2022
Gross Remuneration
Year
Mr. Marshall A. Heinberg
Independent Director
-
2022
Gross Remuneration
Year
Mr. Allen Baharaff
Director, President and Chief Executive Officer
-
2022
Gross Remuneration
Year
Mr. Shmuel Nir
Independent Director
-
2022
Gross Remuneration
Year
Dr. Carol L. Brosgart, M.D.
Independent Director
-
2022
Gross Remuneration
Year
Mr. Amir Poshinski
Independent Director
-
2022
Gross Remuneration
Year

Galmed Pharmaceuticals Ltd FAQ

How is Galmed Pharmaceuticals Ltd today?
Galmed Pharmaceuticals Ltd today is trading in the red, and is down by -1.14% at 1.74.
Galmed Pharmaceuticals Ltd is currently trading down -1.14% on an intraday basis. In the past week the stock fell -30.68%. stock has been down -42.76% in the past quarter and fell -54.69% in the past year. You can view this in the overview section.